Company Overview

Quest Laboratories Ltd is a pharmaceutical manufacturer incorporated in 1998, specializing in diverse therapeutic segments. The company has established itself as a significant player in the Indian pharmaceutical industry, focusing on manufacturing a comprehensive range of pharmaceutical formulations and generic drugs. Quest Laboratories Ltd was originally incorporated under the name "Quest Laboratories Private Limited" on June 01, 1998. Subsequently, its status changed to Public Limited, and the name was updated to "Quest Laboratories Limited" on January 23, 2024, by the Registrar of Companies, Centralised Processing Centre.

Business Operations and Product Portfolio

The Company is engaged in the manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. This diversified product range demonstrates the company's capability to serve multiple therapeutic areas, making it a versatile player in the pharmaceutical sector.

Quest Laboratories also produces a wide array of ethical, generic, and over-the-counter (OTC) drugs in various forms, such as tablets, liquids, oral powders, ORS, ointments, and external liquids. This comprehensive manufacturing capability allows the company to cater to different market segments and consumer needs across various dosage forms.

The company offers facilities for institutional supplies, domestic ethical products, PCD (Propaganda Cum Distribution), contract manufacturing, and exports, with a focus on a wide range of specialized formulations and molecules. Quest Laboratories boasts over 800 Licensed Formulations and 272+ Active Products, along with a significant order book of ₹25 crore from Myanmar. These impressive operational metrics highlight the company's extensive manufacturing capabilities and international market presence.

Financial Performance and Market Position

As of July 31, 2025, the market capitalization of Quest Laboratories Ltd (QUESTLAB) stands at ₹167.15 Crore, positioning it as a small-cap pharmaceutical company. The company trades on both the NSE and BSE under the symbol QUESTLAB. The share price on July 31, 2025, was ₹98.5 on NSE and ₹98.5 on BSE.

The company's recent financial performance shows promising growth. For Q1 FY2026 (unaudited results reported on July 24, 2025), the company reported a Profit of ₹410.43 lakhs and acquired land for expansion valued at ₹321.20 lakhs. Net profit for the quarter ended June 2025 rose by a significant 177.03% to ₹4.10 crore, compared to ₹1.48 crore during the same quarter in the previous year (June 2024).

Key Financial Metrics

- Q1 FY2026 Performance: Profit INR 410.43 lakhs

- Quarterly Profit Growth: Net profit increased by 177.03% in June 2025 quarter YoY.

- Total Revenue (TTM): ₹104 Crore

- Total Profit (TTM): ₹13.6 Crore

- TTM Profit After Tax: ₹10 Crore

- Market Capitalization: ₹167.15 Cr (as of July 31, 2025)

- Promoter Holding: 66.2%

Valuation Metrics

Quest Laboratories presents attractive valuation metrics within the pharmaceutical sector. The P/E ratio as of July 1, 2025, is 11.55 times, which represents a significant 71% discount to its peers' median P/E ratio of 39.70 times. This substantial discount suggests a potential value opportunity for investors.

The company's stock performance shows a 52-week high of ₹160 and a 52-week low of ₹75.15, indicating notable price volatility over the past year.

Strategic Developments and Future Outlook

The company is actively pursuing expansion strategies, as evidenced by the acquisition of land for ₹321.20 lakhs for expansion in Q1 FY2026. Furthermore, the company's July 2025 investor presentation highlights strong growth, the introduction of a new capsule line, plans for a USFDA compliant injectable facility, and export expansion. These initiatives underscore the company's strategic focus on increasing capacity and meeting international regulatory standards.

Shareholding Pattern and Corporate Governance

The Promoter Holding stands at 66.2%, indicating strong promoter confidence in the business. The absence of any promoter pledging in Quest Laboratories Ltd suggests healthy corporate governance practices. The company's management is led by Anil Kumar Sabarwal as the Managing Director.

Operational Efficiency and Challenges

While the company demonstrates strong revenue and profit growth, working capital days have increased significantly from 109 days to 245 days. This indicates potential challenges in working capital management that investors should monitor closely. Additionally, although the company is reporting consistent profits, it is not currently paying dividends, suggesting that earnings are being retained for reinvestment and growth.

Conclusion:

Quest Laboratories Ltd represents a growing pharmaceutical company with a diverse product offering, a growing international presence, and attractive valuation metrics. The company's strategic focus on expansion, regulatory compliance, and operational improvements positions it well for future growth in the competitive pharmaceutical sector. However, investors should carefully consider the working capital management challenges and the company's current non-dividend paying policy when making investment decisions.